Overview
- Ozempic will be sold in 0.25 mg, 0.5 mg and 1 mg pens, with monthly prices of ₹8,800, ₹10,170 and ₹11,175 respectively.
- India’s CDSCO cleared semaglutide for adults with type 2 diabetes in October, and Novo says imported supplies from Denmark are now being distributed nationally.
- The once‑weekly injection is indicated as an adjunct to diet and exercise and is reported to improve glycaemic control, support weight loss, and lower cardiovascular and kidney risks.
- Clinicians and the company urge specialist prescribing and warn against unsupervised or cosmetic use due to side effects such as nausea, vomiting and rarer risks like pancreatitis.
- Core patent protections have lapsed and secondary coverage ends in March 2026, with Indian firms preparing semaglutide generics and rivals like Mounjaro and Wegovy already in the market.